Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

prescription medicines

- PMLiVE

Roche and AstraZeneca to share early trial data

Unique big pharma collaboration aims to increase their R&D efficiency

- PMLiVE

Boehringer files Pradaxa for new VTE indication in Europe

Seeks to add to anticoagulant’s approvals

- PMLiVE

Sanofi and AstraZeneca form cancer research alliances with non-profits

Will work respectively with Curie Institute in France and Cancer Research UK

- PMLiVE

AstraZeneca picks location for global HQ and research base

Decides on the Cambridge Biomedical Campus in UK

- PMLiVE

AstraZeneca and NGM form diabetes/ obesity partnership

Will use MedImmune arm to develop treatments that target gastrointestinal hormones

- PMLiVE

AstraZeneca boosts R&D prospects with Pearl acquisition

Deal to acquire respiratory firm could be worth up to $1.15bn

- PMLiVE

Boehringer says faldaprevir does well in Asian hepatitis C patients

Trial success in patients from Korea, Japan and Taiwan

- PMLiVE

Boehringer invests €35m in research centre in China

Teams up with Shanghai firm to build biopharma facility

- PMLiVE

FDA gives priority review status to BMS/ AZ’s metreleptin

Former obesity prospect has potential in the rare disease lipodystrophy

- PMLiVE

ASCO: Boehringer’s nintedanib boosts survival in lung cancer subset

Trial date demonstrates benefit in NSCLC patients with adenocarcinomas

- PMLiVE

AstraZeneca drops arthritis candidate fostamatinib

Hands rights back to Rigel after late-stage trial disappointment

National Institute for Health and Care Excellence NICE logo

NICE reverses negative guidance for Forxiga in diabetes

Final draft guidance backs the use of BMS/AstraZeneca’s SGLT-2 inhibitor in certain patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links